Lyka Labs Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
LYKALABS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.5 pts less than Nifty Microcap 250 and 3.2 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Lyka Labs has filed its unaudited Q1 FY26 results (quarter ended June 30, 2025). On a standalone basis, revenue from operations fell to ₹2,917.64 lakhs from ₹3,010.47 lakhs a year ago (~3% decline), while net profit after tax dropped sharply to ₹81.42 lakhs from ₹174.96 lakhs (~53% lower YoY). EPS stood at ₹0.22 vs ₹0.49 previously. On a consolidated basis, revenue grew to ₹3,302.54 lakhs (~10% YoY) helped by subsidiaries, but consolidated PAT declined to ₹99.62 lakhs from ₹128.95 lakhs. The subsidiary Lyka BDR International wrote off ₹68.48 lakhs due to a past product quality claim. The board also accepted the resignation of Company Secretary Shekhar R Singh (effective Aug 1, 2025) and appointed Sudit K Parekh & Co. LLP as the new Internal Auditor for FY25-26. Statutory auditors (D. Kothary & Co.) gave an unqualified opinion on the results.
Weak quarter for shareholders — sharp YoY drop in standalone profits and shrinking margins signal pressure on core pharma operations, though consolidated revenue growth from subsidiaries offers some cushion. The management reshuffle (CS exit plus new internal auditor) is routine but worth monitoring for governance continuity ahead of the AGM.